PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) said it will present new Phase 1 clinical data on Teverelix, its investigational long-acting gonadotropin-releasing hormone antagonist, at the American Association of Clinical Endocrinology Annual Meeting April 22-24 in Las Vegas, as the company expands development of the drug for hormone-driven conditions including endometriosis and uterine fibroids.
The company said the presentation will highlight safety, pharmacokinetic, pharmacodynamic and bone turnover data from two Phase 1 studies involving healthy premenopausal women, with findings it said support less frequent dosing and further patient-based studies.
Chief Medical Officer Dr. Faisal Mehmud is scheduled to present the poster Friday, April 24, at 11:40 a.m. Pacific time.
The poster, titled “Evaluation of Teverelix, a Long-Acting GnRH Antagonist: Pharmacokinetics, Pharmacodynamics, Bone Turnover and Safety in Two Phase I Studies in Healthy Female Volunteer,” is based on two studies known as TEVERELIX HFV1 and HFV2.
According to the company, the trials were conducted in Germany and enrolled a total of 48 healthy premenopausal women who received a single subcutaneous dose of Teverelix.
Medicus said the data showed predictable, dose-dependent suppression of estradiol, with some participants reaching levels within what it described as the clinically relevant Barbieri therapeutic window of about 30 to 50 picograms per milliliter.
The company said the pharmacokinetic profile was consistent with a depot formulation and could support infrequent dosing strategies.
According to Medicus, the studies showed rapid initial absorption, with time to maximum concentration ranging from about 0.5 to two hours, sustained exposure with a secondary peak at one to three weeks, and a terminal half-life of about 14 to 23 days.
The company also said bone turnover markers, including DPD and NTx, remained within normal ranges, with a 10% change at Day 29.
No unexpected safety signals were observed across the two studies, Medicus said.
The company said the findings provide a mechanistic and pharmacologic basis for patient-based studies across multiple indications and could support a broader development strategy for Teverelix in women’s health and other therapeutic areas.
Teverelix is being developed for hormone-driven conditions, with Medicus identifying endometriosis and uterine fibroids as potential women’s health applications.
The company said it is exploring a development program for symptomatic endometriosis, which it described as an estrogen-dependent condition with significant unmet need.
Medicus said that program is planned in collaboration with Omics Labs in the United Arab Emirates and would use a genomics-enabled clinical development strategy aimed at improving patient selection and therapeutic response.
The company said the approach may include hormonal pathway profiling, biomarker-based patient stratification, and clinical trial design intended to improve signal detection and development efficiency.
Medicus said no long-acting injectable GnRH antagonists are currently approved for endometriosis, which it said could position Teverelix as a potential first long-acting injectable therapy in that market if development succeeds.
In addition to Teverelix, Medicus is advancing SkinJect, an investigational localized immuno-oncology product for non-melanoma skin diseases including basal cell carcinoma and Gorlin syndrome.
The company also disclosed several recent collaborations tied to broader pipeline development.
In August 2025, Medicus said it entered a non-binding memorandum of understanding with Helix Nanotechnologies regarding possible development or commercial arrangements involving mRNA technology and the company’s microneedle array platform.
In October 2025, the company announced a collaboration with the Gorlin Syndrome Alliance aimed at pursuing an Expanded Access IND program for SkinJect in patients with multiple or inoperable basal cell carcinomas.
In December 2025, Medicus said it signed a non-binding letter of intent with Reliant AI Inc. to develop an AI-based clinical data analytics platform that could support clinical-site selection, patient stratification and enrollment forecasting, including for a Teverelix study planned for 2026.
More information about the Teverelix abstract is available at https://aace2026.d365.events/education/posters/41c0e4cf-130f-46be-8910-0d7a1b2a8dc1.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.